Condition: Advanced Soft-tissue Sarcoma
Intervention: Drug: Camsirubicin
Sponsor: Monopar Therapeutics
Not yet recruiting
Feeds
6810 items (6810 unread) in 74 feeds
Acinar Cell Carcinoma
(81 unread)
Acinic Cell Carcinoma
(46 unread)
Adenoid Cystic Carcinoma
(159 unread)
Adrenal Gland Cancer
(533 unread)
Ampulla Of Vater
(68 unread)
Anal Cancer
(425 unread)
Angiosarcoma
(153 unread)
Appendix Cancer
(104 unread)
Bile Duct Cancer
(845 unread)
Brain and CNS
(878 unread)
Carcinoid
(266 unread)
Endocrine/Neuroendocrine
(808 unread)
Gall Bladder Cancer
(381 unread)
Hemangioendothelioma
(215 unread)
Hepatoblastoma
(129 unread)
Pancreas
(117 unread)
Phyllodes
(105 unread)
PMP and Mucinous Tumors
(114 unread)
Rhabdomyosarcoma
(246 unread)
Sarcoma
(1137 unread)
Trial - Sarcoma (92 unread)
-
Camsirubicin + Pegfilgrastim to Determine MTD in ASTS
Posted: September 14th, 2021, 2:00pm GMT
-
Lurbinectedin With or Without Irinotecan in Treating Patients With Relapsed or High Risk Metastatic Ewing Sarcoma
Posted: September 13th, 2021, 2:00pm GMT
Conditions: Metastatic Ewing Sarcoma; Recurrent Ewing Sarcoma
Interventions: Procedure: Fine-Needle Aspiration; Drug: Irinotecan; Drug: Irinotecan Hydrochloride; Drug: Lurbinectedin
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Not yet recruiting -
IACS-6274 With or Without Pembrolizumab for the Treatment of Advanced Solid Tumors
Posted: September 10th, 2021, 2:00pm GMT
Conditions: Advanced Endometrial Carcinoma; Advanced Head and Neck Squamous Cell Carcinoma; Advanced Malignant Solid Neoplasm; Advanced Melanoma; Advanced Ovarian Clear Cell Adenocarcinoma; Chondrosarcoma; Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; Pathologic Stage III Cutaneous Melanoma AJCC v8; Pathologic Stage IIIA Cutaneous Melanoma AJCC v8; Pathologic Stage IIIB Cutaneous Melanoma AJCC v8; Pathologic Stage IIIC Cutaneous Melanoma AJCC v8; Pathologic Stage IIID Cutaneous Melanoma AJCC v8; Pathologic Stage IV Cutaneous Melanoma AJCC v8; Refractory Endometrial Carcinoma; Refractory Head and Neck Squamous Cell Carcinoma; Refractory High Grade Ovarian Serous Adenocarcinoma; Refractory Melanoma; Refractory Ovarian Clear Cell Adenocarcinoma; Stage III Ovarian Cancer AJCC v8; Stage III Uterine Corpus Cancer AJCC v8; Stage IIIA Ovarian Cancer AJCC v8; Stage IIIA Uterine Corpus Cancer AJCC v8; Stage IIIA1 Ovarian Cancer AJCC v8; Stage IIIA2 Ovarian Cancer AJCC v8; Stage IIIB Ovarian Cancer AJCC v8; Stage IIIB Uterine Corpus Cancer AJCC v8; Stage IIIC Ovarian Cancer AJCC v8; Stage IIIC Uterine Corpus Cancer AJCC v8; Stage IIIC1 Uterine Corpus Cancer AJCC v8; Stage IIIC2 Uterine Corpus Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Uterine Corpus Cancer AJCC v8; Stage IVA Ovarian Cancer AJCC v8; Stage IVA Uterine Corpus Cancer AJCC v8; Stage IVB Ovarian Cancer AJCC v8; Stage IVB Uterine Corpus Cancer AJCC v8
Interventions: Drug: Glutaminase Inhibitor IPN60090; Biological: Pembrolizumab
Sponsor: M.D. Anderson Cancer Center
Recruiting -
A Phase I Trial of T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers
Posted: September 6th, 2021, 2:00pm GMT
Condition: Kita-kyushu Lung Cancer Antigen 1, Human
Interventions: Drug: IL-2 (Aldesleukin); Drug: Cyclophosphamide; Biological: KK-LC-1 TCR; Drug: Fludarabine
Sponsor: National Cancer Institute (NCI)
Not yet recruiting -
Comparing Carbon Ion Therapy, Surgery, and Proton Therapy for the Management of Pelvic Sarcomas Involving the Bone, the PROSPER Study
Posted: September 2nd, 2021, 2:00pm GMT
Conditions: Bone Sarcoma; Chondrosarcoma; Chordoma; Ewing Sarcoma of Bone; Pelvic Rhabdomyosarcoma
Interventions: Other: Electronic Health Record Review; Other: Quality-of-Life Assessment
Sponsors: Mayo Clinic; National Cancer Institute (NCI)
Not yet recruiting -
Molecular Basis of Langerhans and Non-Langerhans Cell Histiocytic Neoplasms and Castleman Disease
Posted: August 31st, 2021, 2:00pm GMT
Conditions: Histiocytic Disorders; Castleman's Disease (CD); Langerhans Cell Histiocytosis (LCH); Erdhiem Chester Disease (ECD); Rosai-Dorfman Disease (RDD); Indeterminate Dendritic Cell Tumor; Interdigitating Dendritic Cell Sarcoma; Follicular Dendritic Cell Sarcoma (FDCS); Fibroblastic Reticular Cell Tumor; Unicentric Castleman Disease; Multicentric Castleman Disease Including TAFRO
Intervention: Diagnostic Test: Genetic testing
Sponsor: Case Comprehensive Cancer Center
Not yet recruiting -
Sintilimab for the Treatment of Locally Advanced, Metastatic, or Recurrent Angiosarcoma, the SiARa Cancer Study
Posted: August 30th, 2021, 2:00pm GMT
Conditions: Locally Advanced Angiosarcoma; Metastatic Angiosarcoma; Recurrent Angiosarcoma
Interventions: Other: Quality-of-Life Assessment; Biological: Sintilimab
Sponsor: M.D. Anderson Cancer Center
Not yet recruiting -
Perioperative Use of Tranexamic (TXA) in Bone Tumor Surgery Reduce Blood Loss and Transfusion Requirements.
Posted: August 27th, 2021, 2:00pm GMT
Conditions: Ewing Sarcoma of Bone; Osteosarcoma
Interventions: Drug: Tranexamic acid injection; Drug: Saline
Sponsor: Children's Cancer Hospital Egypt 57357
Recruiting -
Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation
Posted: August 26th, 2021, 2:00pm GMT
Conditions: Solid Tumor; ARID1A Gene Mutation
Intervention: Drug: Tazemetostat
Sponsors: Prisma Health-Upstate; Epizyme, Inc.
Not yet recruiting -
Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS Study
Posted: August 25th, 2021, 2:00pm GMT
Conditions: Locally Advanced Osteosarcoma; Metastatic Osteosarcoma; Recurrent Osteosarcoma; Refractory Osteosarcoma; Unresectable Osteosarcoma
Interventions: Biological: Atezolizumab; Drug: Cabozantinib
Sponsor: M.D. Anderson Cancer Center
Not yet recruiting -
Sintilimab for the Treatment of Locally Advanced, Metastatic, Recurrent, or Unresectable Undifferentiated Pleomorphic Sarcoma, SiARa Cancer Study
Posted: August 23rd, 2021, 2:00pm GMT
Conditions: Locally Advanced Undifferentiated Pleomorphic Sarcoma; Metastatic Undifferentiated Pleomorphic Sarcoma; Recurrent Undifferentiated Pleomorphic Sarcoma; Unresectable Undifferentiated Pleomorphic Sarcoma
Intervention: Biological: Sintilimab
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting -
Mutant Kirsten Rat Sarcoma (KRAS) -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer
Posted: August 19th, 2021, 2:00pm GMT
Conditions: High Risk Cancer; Pancreatic Cancer
Intervention: Drug: KRAS peptide vaccine
Sponsors: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Stand Up To Cancer
Not yet recruiting -
A Phase I, Study Evaluating the Safety, Tolerability, PK, and Efficacy of GH35 in Patients With Solid Tumors With KRAS Mutation
Posted: August 18th, 2021, 2:00pm GMT
Conditions: AdvAdvanced Solid Tumors; Kirsten Rat Sarcoma
Intervention: Drug: GH35 Tablet
Sponsor: Suzhou Genhouse Bio Co., Ltd.
Not yet recruiting -
A Clinical Trial to Evaluate the Safety and Efficacy of AL2846 Capsules in Chinese Patients With Type I Neurofibromatosis
Posted: August 18th, 2021, 2:00pm GMT
Condition: Neurofibromatosis and Malignant Peripheral Nerve Sheath Tumors
Intervention: Drug: AL2846 capsules
Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Not yet recruiting -
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies
Posted: August 16th, 2021, 2:00pm GMT
Condition: Solid Malignancies
Interventions: Drug: GS-9716; Drug: Docetaxel; Drug: Sacituzumab Govitecan-hziy; Drug: Gemcitabine
Sponsor: Gilead Sciences
Not yet recruiting -
Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
Posted: August 11th, 2021, 2:00pm GMT
Conditions: Bile Duct Cancer; Gall Bladder Cancer; Breast Cancer; Neuroendocrine Tumors; Ovarian Cancer; Pancreatic Adenocarcinoma; Soft Tissue Sarcoma; Vulvar Cancer; Prostate Cancer
Interventions: Drug: Atezolizumab; Drug: Tivozanib
Sponsors: University of Florida; Genentech, Inc.; Aveo Oncology Pharmaceuticals
Not yet recruiting -
A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)
Posted: August 11th, 2021, 2:00pm GMT
Conditions: Ovarian Cancer; Ovarian Neoplasms; Ovarian Carcinoma; Endometrial Cancer; Colorectal Cancer; Gastric Cancer; Gastroesophageal Junction Adenocarcinoma; Gastric Adenocarcinoma; TNBC - Triple-Negative Breast Cancer; Triple Negative Breast Cancer; Cholangiocarcinoma; Bile Duct Cancer; Colon Cancer; Colon Cancer Stage; Colon Neoplasm; Colon Adenocarcinoma; Colon Rectal Cancer; Colon Cancer Liver Metastasis; Colorectal Neoplasms; Colorectal Carcinoma; Colorectal Adenocarcinoma; Colorectal Cancer Metastatic; Colorectal Cancer Stage IV; Rectum Cancer; Rectum Neoplasm; Rectum Carcinoma; Rectal Cancer; Rectal Neoplasms; Rectal Adenocarcinoma; Rectal Cancer Stage; Rectal Cancer Metastatic; Rectal Cancer Stage III; Esophagus Cancer; Esophageal Cancer; Esophageal Neoplasms; Gastric Cancer Stage; Breast Cancer; Breast Neoplasm; Breast Adenocarcinoma; Breast Cancer Stage IV; Breast Cancer Stage; Breast Cancer Metastatic; Breast Cancer Invasive; Triple Negative Breast Neoplasms; Intrahepatic Cholangiocarcinoma; Intrahepatic Cholangiocarcinoma Recurrent; Hilar Cholangiocarcinoma; Distal Cholangiocarcinoma; Ovary Cancer; Ovary Neoplasm; Ovary Disease; Ovary Metastasis; Ovarian Diseases; Ovarian Cancer Stage; Ovarian Epithelial Cancer; Ovarian Adenocarcinoma; Ovarian Serous Adenocarcinoma; Ovarian Neoplasm Epithelial; Ovarian Cancer Recurrent; Endometrial Diseases; Endometrial Adenocarcinoma; Endometrial Carcinosarcoma; Endometrial Clear Cell Adenocarcinoma; Endometrioid Adenocarcinoma; Endometrial Neoplasms; Endometrial Cancer Recurrent; Endometrioid Tumor; Fallopian Tube Cancer; Peritoneal Cancer
Intervention: Drug: ELU001
Sponsor: Elucida Oncology
Recruiting -
A Trial of TTI-621 in Combination With Doxorubicin in Patients With Leiomyosarcoma
Posted: August 9th, 2021, 2:00pm GMT
Condition: Leiomyosarcoma
Interventions: Drug: TTI-621; Drug: Doxorubicin
Sponsor: Trillium Therapeutics Inc.
Recruiting -
HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma
Posted: August 6th, 2021, 2:00pm GMT
Conditions: Sarcoma; HER-2 Protein Overexpression
Interventions: Genetic: cells; Drug: Pembrolizumab Injectable Product; Drug: Nivolumab Injectable Product; Drug: Lymphodepletion Chemotherapy
Sponsors: Baylor College of Medicine; Center for Cell and Gene Therapy, Baylor College of Medicine; The Faris Foundation USA; Stand Up To Cancer; Triumph Over Kid Cancer Foundation; St. Baldrick's Foundation
Not yet recruiting -
A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma
Posted: August 6th, 2021, 2:00pm GMT
Conditions: Alveolar Rhabdomyosarcoma; Botryoid-Type Embryonal Rhabdomyosarcoma; Embryonal Rhabdomyosarcoma; Rhabdomyosarcoma; Solid Alveolar Rhabdomyosarcoma; Spindle Cell Rhabdomyosarcoma; Spindle Cell/Sclerosing Rhabdomyosarcoma
Interventions: Drug: Cyclophosphamide; Biological: Dactinomycin; Radiation: Radiation Therapy; Drug: Vincristine Sulfate; Drug: Vinorelbine Tartrate
Sponsor: Children's Oncology Group
Not yet recruiting -
Analysis of the Molecular Profile of the Mixofibrosarcoma of the Extremities
Posted: August 5th, 2021, 2:00pm GMT
Condition: Sarcoma,Soft Tissue
Intervention: Other: case series review of clinical and histological data
Sponsor: Istituto Ortopedico Rizzoli
Not yet recruiting -
Ultrasound Evaluation of the Myometrium Using the MUSA Terminology Comparison With Histology
Posted: August 4th, 2021, 2:00pm GMT
Conditions: Myoma;Uterus; Sarcoma Uterus
Intervention: Procedure: Hysterectomy
Sponsor: Universitaire Ziekenhuizen Leuven
Recruiting -
Using QPOP to Predict Treatment for Sarcomas and Melanomas
Posted: August 3rd, 2021, 2:00pm GMT
Conditions: Sarcoma; Melanoma
Intervention:
Sponsor: National Cancer Centre, Singapore
Recruiting -
FHD-609 in Subjects With Advanced Synovial Sarcoma
Posted: July 16th, 2021, 2:00pm GMT
Condition: Advanced Synovial Sarcoma
Intervention: Drug: FHD-609
Sponsor: Foghorn Therapeutics Inc.
Recruiting -
Exercise Intervention for Bone Tumor Patients
Posted: July 15th, 2021, 2:00pm GMT
Condition: Bone Sarcoma
Interventions: Behavioral: Exercise therapy; Other: Information
Sponsors: Universität Duisburg-Essen; Ruhr University of Bochum
Recruiting -
Accuracy of the Preoperative Molecular Diagnosis of Uterine Tumors by Liquid Biopsy
Posted: June 23rd, 2021, 2:00pm GMT
Conditions: Leiomyoma, Uterine; Leiomyosarcoma Uterus
Interventions: Procedure: Collection of Leiomyoma samples; Procedure: Collection of Leiomyosarcoma samples; Procedure: Collection of control samples
Sponsor: Igenomix
Recruiting -
APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion
Posted: June 9th, 2021, 2:00pm GMT
Conditions: Fallopian Tube Carcinosarcoma; Fallopian Tube Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Ovarian Carcinosarcoma; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Serous Adenocarcinoma; Primary Peritoneal Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma
Interventions: Biological: Bevacizumab; Biological: Pegcetacoplan; Biological: Pembrolizumab; Other: Quality-of-Life Assessment; Other: Questionnaire Administration
Sponsor: Roswell Park Cancer Institute
Not yet recruiting -
NT-I7 for Kaposi Sarcoma in Patients With or Without HIV
Posted: May 19th, 2021, 2:00pm GMT
Conditions: AIDS-Related Kaposi Sarcoma; HIV Infection; Kaposi Sarcoma
Intervention: Biological: Efineptakin alfa
Sponsors: Fred Hutchinson Cancer Research Center; Cancer Immunotherapy Trials Network
Not yet recruiting -
Study of Liposomal Annamycin for the Treatment of Subjects With Soft-Tissue Sarcomas (STS) With Pulmonary Metastases
Posted: May 14th, 2021, 2:00pm GMT
Conditions: Sarcoma,Soft Tissue; Pulmonary Metastasis
Intervention: Drug: Liposomal Annamycin (L-Annamycin)
Sponsor: Moleculin Biotech, Inc.
Recruiting -
RegoNivo vs Standard of Care Chemotherapy in AGOC
Posted: May 10th, 2021, 2:00pm GMT
Condition: Gastro-Oesophageal Cancer
Interventions: Drug: Regorafenib; Biological: Nivolumab; Drug: Docetaxel; Drug: Paclitaxel; Drug: Irinotecan; Drug: Trifluridine/Tipracil
Sponsors: Australasian Gastro-Intestinal Trials Group; Bayer; Bristol-Myers Squibb; University of Sydney; Academic and Community Cancer Research United; Taiwanese Cooperative Oncology Group; Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Recruiting -
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Posted: April 20th, 2021, 2:00pm GMT
Conditions: Colorectal Carcinoma; Endometrial Carcinoma; Melanoma; Neuroblastoma; Ovarian Carcinoma; Pancreatic Ductal Adenocarcinoma; Recurrent Desmoid Fibromatosis; Recurrent Ewing Sarcoma; Recurrent Hepatoblastoma; Recurrent Hepatocellular Carcinoma; Recurrent Malignant Solid Neoplasm; Recurrent Non-Hodgkin Lymphoma; Recurrent Osteosarcoma; Refractory Desmoid Fibromatosis; Refractory Ewing Sarcoma; Refractory Hepatoblastoma; Refractory Hepatocellular Carcinoma; Refractory Malignant Solid Neoplasm; Refractory Non-Hodgkin Lymphoma; Refractory Osteosarcoma; Solid Pseudopapillary Neoplasm of the Pancreas; Wilms Tumor
Intervention: Drug: Tegavivint
Sponsor: Children's Oncology Group
Not yet recruiting -
SARC038: Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma
Posted: March 18th, 2021, 2:00pm GMT
Conditions: Osteosarcoma; Osteosarcoma in Children; Osteosarcoma Recurrent; Osteosarcoma Metastatic
Interventions: Drug: Regorafenib 40 MG; Drug: Regorafenib 20MG; Drug: Nivolumab
Sponsor: Sarcoma Alliance for Research through Collaboration
Recruiting -
Sequential Neoadjuvant Chemotherapy in Soft Tissue Sarcoma
Posted: March 1st, 2021, 3:00pm GMT
Condition: Soft Tissue Sarcoma
Interventions: Drug: Ifosfamide; Drug: Doxorubicin
Sponsors: Oslo University Hospital; Haukeland University Hospital
Recruiting -
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS)
Posted: February 24th, 2021, 3:00pm GMT
Condition: Amyotrophic Lateral Sclerosis
Interventions: Drug: ION363; Drug: Placebo
Sponsor: Ionis Pharmaceuticals, Inc.
Recruiting -
A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB)
Posted: February 12th, 2021, 3:00pm GMT
Conditions: Glioblastoma; Glioblastoma Multiforme
Interventions: Drug: BPM31510; Other: Vitamin K1; Drug: Temozolomide (TMZ); Radiation: Radiation
Sponsor: Berg, LLC
Recruiting -
Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial Malignancies
Posted: December 2nd, 2020, 3:00pm GMT
Conditions: Sarcomas; Melanomas; Germ Cell Tumors; Epithelial Malignancies (Excluding Lung and Renal Cell Carcinomas); Pulmonary Metastases
Interventions: Device: AeroEclipse II Breath Actuated Nebulizer; Drug: Bintrafusp alfa; Drug: Azacytidine
Sponsor: National Cancer Institute (NCI)
Not yet recruiting -
A Study to Test Different Doses of BI 1701963 in Combination With Irinotecan in People With Advanced Bowel Cancer With Kirsten Rat Sarcoma Viral Oncogene Homologue (KRAS) Mutation
Posted: November 13th, 2020, 3:00pm GMT
Condition: Metastatic Colorectal Cancer (CRC)
Interventions: Drug: BI 1701963; Drug: Camptosar®
Sponsor: Boehringer Ingelheim
Recruiting -
Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
Posted: October 8th, 2020, 2:00pm GMT
Conditions: Metastatic Solid Tumor; Colorectal Cancer; Neuroendocrine Tumors; Small Cell Lung Cancer; Gastric Cancer; Soft Tissue Sarcoma
Interventions: Drug: Surufatinib and Tislelizumab _ Part 1; Drug: Surufatinib and Tislelizumab _ Part 2
Sponsors: Hutchison Medipharma Limited; BeiGene
Recruiting -
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 Mutations
Posted: August 20th, 2020, 2:00pm GMT
Conditions: Cholangiocarcinoma; Chondrosarcoma; Glioma; Any Solid Tumor
Intervention: Drug: LY3410738
Sponsors: Eli Lilly and Company; Loxo Oncology, Inc.
Recruiting -
ENVASARC: Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma
Posted: July 21st, 2020, 2:00pm GMT
Conditions: Undifferentiated Pleomorphic Sarcoma; Myxofibrosarcoma
Interventions: Biological: Envafolimab; Drug: Ipilimumab
Sponsor: Tracon Pharmaceuticals Inc.
Recruiting -
X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and Melanoma
Posted: May 15th, 2020, 2:00pm GMT
Condition: Advanced Cancer
Intervention: Combination Product: X-PACT
Sponsor: Immunolight, LLC
Not yet recruiting -
Trial in Patients With Metastatic or Locally Advanced Leiomyosarcoma
Posted: May 12th, 2020, 2:00pm GMT
Conditions: Leiomyosarcoma of Ovary; Soft Tissue Sarcoma
Interventions: Drug: Trabectedin; Drug: Gemcitabine; Drug: No Intervention: Observational Cohort
Sponsors: Italian Sarcoma Group; PharmaMar
Not yet recruiting -
Testing the Addition of Nivolumab to Chemotherapy in Treatment of Soft Tissue Sarcoma
Posted: April 9th, 2020, 2:00pm GMT
Conditions: Skin Angiosarcoma; Skin Radiation-Related Angiosarcoma; Visceral Angiosarcoma
Interventions: Drug: Cabozantinib S-malate; Biological: Nivolumab; Drug: Paclitaxel; Other: Quality-of-Life Assessment; Other: Questionnaire Administration
Sponsor: National Cancer Institute (NCI)
Recruiting -
A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg
Posted: April 3rd, 2020, 2:00pm GMT
Conditions: Sarcoma; Myxofibrosarcoma; Undifferentiated Pleomorphic Sarcoma; Alveolar Soft Part Sarcoma
Interventions: Procedure: Isolated Limb Infusion; Drug: Pembrolizumab; Drug: infusion of melphalan and dactinomycin
Sponsor: Memorial Sloan Kettering Cancer Center
Recruiting -
Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial
Posted: March 25th, 2020, 2:00pm GMT
Conditions: Hematopoietic and Lymphoid Cell Neoplasm; Recurrent Ependymoma; Recurrent Ewing Sarcoma; Recurrent Hepatoblastoma; Recurrent Histiocytic and Dendritic Cell Neoplasm; Recurrent Langerhans Cell Histiocytosis; Recurrent Lymphoma; Recurrent Malignant Germ Cell Tumor; Recurrent Malignant Glioma; Recurrent Malignant Solid Neoplasm; Recurrent Medulloblastoma; Recurrent Neuroblastoma; Recurrent Non-Hodgkin Lymphoma; Recurrent Osteosarcoma; Recurrent Peripheral Primitive Neuroectodermal Tumor; Recurrent Rhabdoid Tumor; Recurrent Rhabdomyosarcoma; Recurrent Soft Tissue Sarcoma; Recurrent WHO Grade II Glioma; Refractory Ependymoma; Refractory Ewing Sarcoma; Refractory Hepatoblastoma; Refractory Histiocytic and Dendritic Cell Neoplasm; Refractory Langerhans Cell Histiocytosis; Refractory Lymphoma; Refractory Malignant Germ Cell Tumor; Refractory Malignant Glioma; Refractory Malignant Solid Neoplasm; Refractory Medulloblastoma; Refractory Neuroblastoma; Refractory Non-Hodgkin Lymphoma; Refractory Osteosarcoma; Refractory Peripheral Primitive Neuroectodermal Tumor; Refractory Rhabdoid Tumor; Refractory Rhabdomyosarcoma; Refractory Soft Tissue Sarcoma; Refractory WHO Grade II Glioma; Wilms Tumor
Intervention: Drug: Selpercatinib
Sponsors: National Cancer Institute (NCI); Children's Oncology Group
Recruiting -
Study on Trabectedin in Advanced Rearranged Mesenchymal Chondrosarcoma
Posted: March 12th, 2020, 2:00pm GMT
Condition: Mesenchymal Chondrosarcoma
Intervention: Drug: Trabectedin
Sponsors: Italian Sarcoma Group; PharmaMar
Not yet recruiting -
NHS-IL12 Monotherapy and in Combination With M7824 in Advanced Kaposi Sarcoma
Posted: March 10th, 2020, 2:00pm GMT
Condition: Kaposi Sarcoma
Interventions: Drug: NHS-IL12; Drug: NHS-IL12+M7824
Sponsor: National Cancer Institute (NCI)
Recruiting -
Study of AMG 650 in Adult Participants With Advanced Solid Tumors
Posted: March 3rd, 2020, 3:00pm GMT
Condition: Advanced Solid Tumors
Intervention: Drug: AMG 650
Sponsor: Amgen
Recruiting -
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
Posted: February 26th, 2020, 3:00pm GMT
Conditions: Recurrent Adrenal Gland Pheochromocytoma; Recurrent Ectomesenchymoma; Recurrent Ependymoma; Recurrent Ewing Sarcoma; Recurrent Hepatoblastoma; Recurrent Kidney Wilms Tumor; Recurrent Langerhans Cell Histiocytosis; Recurrent Malignant Germ Cell Tumor; Recurrent Malignant Glioma; Recurrent Medulloblastoma; Recurrent Melanoma; Recurrent Neuroblastoma; Recurrent Non-Hodgkin Lymphoma; Recurrent Osteosarcoma; Recurrent Peripheral Primitive Neuroectodermal Tumor; Recurrent Rhabdoid Tumor; Recurrent Rhabdoid Tumor of the Kidney; Recurrent Rhabdomyosarcoma; Recurrent Soft Tissue Sarcoma; Recurrent Thyroid Gland Carcinoma; Recurrent WHO Grade II Glioma; Refractory Adrenal Gland Pheochromocytoma; Refractory Ependymoma; Refractory Ewing Sarcoma; Refractory Hepatoblastoma; Refractory Langerhans Cell Histiocytosis; Refractory Malignant Germ Cell Tumor; Refractory Malignant Glioma; Refractory Medulloblastoma; Refractory Melanoma; Refractory Neuroblastoma; Refractory Non-Hodgkin Lymphoma; Refractory Osteosarcoma; Refractory Peripheral Primitive Neuroectodermal Tumor; Refractory Rhabdoid Tumor; Refractory Rhabdoid Tumor of the Kidney; Refractory Rhabdomyosarcoma; Refractory Soft Tissue Sarcoma; Refractory Thyroid Gland Carcinoma; Refractory WHO Grade II Glioma
Intervention: Drug: Tipifarnib
Sponsor: National Cancer Institute (NCI)
Recruiting -
A Study of Abemaciclib (LY2835219) in Combination With Temozolomide and Irinotecan and Abemaciclib in Combination With Temozolomide in Children and Young Adult Participants With Solid Tumors
Posted: January 23rd, 2020, 3:00pm GMT
Conditions: Relapsed Solid Tumor; Refractory Solid Tumor
Interventions: Drug: Abemaciclib; Drug: Irinotecan; Drug: Temozolomide
Sponsor: Eli Lilly and Company
Recruiting -
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
Posted: January 10th, 2020, 3:00pm GMT
Conditions: Advanced Solid Tumors; Metastatic Pancreatic Cancer; Pediatric Solid Tumor; Advanced Breast Cancer; Malignant Peripheral Nerve Sheath Tumor
Intervention: Drug: Metarrestin
Sponsor: National Cancer Institute (NCI)
Recruiting -
Development of a Predictive Model for Early Differential Diagnosis of Uterine Leiomyomas and Leiomyosarcomas
Posted: January 2nd, 2020, 3:00pm GMT
Conditions: Leiomyoma; Leiomyosarcoma
Intervention: Procedure: Biopsy and peripheral blood collection
Sponsor: Igenomix
Recruiting -
Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)
Posted: December 12th, 2019, 3:00pm GMT
Conditions: Recurrent Ependymoma; Recurrent Ewing Sarcoma; Recurrent Hepatoblastoma; Recurrent Langerhans Cell Histiocytosis; Recurrent Malignant Germ Cell Tumor; Recurrent Malignant Glioma; Recurrent Malignant Solid Neoplasm; Recurrent Medulloblastoma; Recurrent Neuroblastoma; Recurrent Non-Hodgkin Lymphoma; Recurrent Osteosarcoma; Recurrent Peripheral Primitive Neuroectodermal Tumor; Recurrent Rhabdoid Tumor; Recurrent Rhabdomyosarcoma; Recurrent Soft Tissue Sarcoma; Recurrent WHO Grade II Glioma; Refractory Ependymoma; Refractory Ewing Sarcoma; Refractory Hepatoblastoma; Refractory Langerhans Cell Histiocytosis; Refractory Malignant Germ Cell Tumor; Refractory Malignant Glioma; Refractory Malignant Solid Neoplasm; Refractory Medulloblastoma; Refractory Neuroblastoma; Refractory Non-Hodgkin Lymphoma; Refractory Osteosarcoma; Refractory Peripheral Primitive Neuroectodermal Tumor; Refractory Rhabdoid Tumor; Refractory Rhabdomyosarcoma; Refractory Soft Tissue Sarcoma; Refractory WHO Grade II Glioma; Wilms Tumor
Intervention: Drug: Ivosidenib
Sponsors: National Cancer Institute (NCI); Children's Oncology Group
Recruiting -
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
Posted: December 4th, 2019, 3:00pm GMT
Conditions: Advanced Solid Tumors; Kirsten Rat Sarcoma (KRAS) pG12C Mutation
Interventions: Drug: Sotorasib; Drug: AMG 404; Drug: trametinib; Drug: RMC-4630; Drug: afatinib; Drug: pembrolizumab; Drug: panitumumab; Drug: carboplatin, pemetrexed, docetaxel; Drug: atezolizumab; Drug: everolimus; Drug: palbociclib; Drug: MVASI® (bevacizumab-awwb); Drug: TNO155; Drug: FOLFIRI; Drug: FOLFOX
Sponsor: Amgen
Recruiting -
A Study to Compare the Efficacy and Safety of Ifosfamide and Etoposide With or Without Lenvatinib in Children, Adolescents and Young Adults With Relapsed and Refractory Osteosarcoma
Posted: November 6th, 2019, 3:00pm GMT
Condition: Osteosarcoma
Interventions: Drug: Lenvatinib; Drug: Ifosfamide; Drug: Etoposide
Sponsors: Eisai Inc.; Merck Sharp & Dohme Corp.
Recruiting -
A Pilot Study to Explore the Role of Gut Flora in Colorectal Cancer
Posted: November 1st, 2019, 2:00pm GMT
Conditions: Colorectal Cancer; Colorectal Neoplasms; Colorectal Carcinoma; Colorectal Adenocarcinoma; Colorectal Cancer Metastatic; Colorectal Sarcoma
Intervention: Other: No intervention
Sponsor: ProgenaBiome
Recruiting -
Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body
Posted: October 29th, 2019, 2:00pm GMT
Condition: Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion
Intervention: Drug: larotrectinib(Vitrakvi, BAY2757556)
Sponsor: Bayer
Recruiting -
Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders
Posted: September 6th, 2019, 2:00pm GMT
Conditions: Langerhan's Cell Histiocytosis; Juvenile Xanthogranuloma; Erdheim-Chester Disease; Rosai Dorfman Disease; Neuro-Degenerative Disease; Histiocytic Sarcoma; Histiocytic Disorders, Malignant
Intervention: Drug: Cobimetinib
Sponsors: Carl Allen; Baylor College of Medicine; North American Consortium for Histiocytosis; Genentech, Inc.
Recruiting -
Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
Posted: August 5th, 2019, 2:00pm GMT
Conditions: Synovial Sarcoma; Myxoid Liposarcoma
Intervention: Genetic: afamitresgene autoleucel (previously ADP-A2M4)
Sponsor: Adaptimmune
Recruiting -
Olaratumab (LY3012207) Patient Access for Soft Tissue Sarcoma
Posted: June 21st, 2019, 2:00pm GMT
Condition: Soft Tissue Sarcoma
Intervention: Drug: Olaratumab
Sponsor: Eli Lilly and Company
Available -
A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma
Posted: May 31st, 2019, 2:00pm GMT
Condition: Hepatocellular Carcinoma
Interventions: Drug: Tivozanib; Drug: Durvalumab
Sponsors: AVEO Pharmaceuticals, Inc.; AstraZeneca
Recruiting -
A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 in Combination With BI 754091 (Ezabenlimab) and 754111 or BI 907828 in Combination With BI 754091 (Ezabenlimab)
Posted: May 28th, 2019, 2:00pm GMT
Condition: Neoplasms
Interventions: Drug: BI 907828; Drug: BI 754091; Drug: BI 754111
Sponsor: Boehringer Ingelheim
Recruiting -
Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients
Posted: March 14th, 2019, 2:00pm GMT
Conditions: Colorectal Cancer; ADCC
Intervention: Drug: Folfiri/Cetuximab
Sponsor: National Cancer Institute, Naples
Recruiting -
Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda
Posted: March 6th, 2019, 3:00pm GMT
Conditions: Burkitt Lymphoma; KSHV-associated Multicentric Castleman Disease; Diffuse Large B-Cell Lymphoma
Interventions: Biological: Rituximab and Hyaluronidase Human; Drug: Cyclophosphamide; Drug: Vincristine; Drug: Methotrexate; Drug: Doxorubicin; Drug: Doxorubicin Hydrochloride; Drug: Prednisone; Drug: Etoposide; Biological: Rituximab
Sponsor: Fred Hutchinson Cancer Research Center
Recruiting -
PROactive Evaluation of Function to Avoid CardioToxicity
Posted: March 5th, 2019, 3:00pm GMT
Conditions: Cardiotoxicity; Breast Cancer; Lymphoma; Sarcoma; Leukemia; Myeloma; Lung Cancer
Intervention: Device: MyoStrain®
Sponsors: Washington University School of Medicine; Myocardial Solutions
Recruiting -
A Study of APG-115 in Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors
Posted: August 2nd, 2018, 2:00pm GMT
Conditions: Unresectable or Metastatic Melanoma or Advanced Solid Tumors; Melanoma; Uveal Melanoma; Non Small Cell Lung Cancer; ATM Gene Mutation; P53 Mutation; MDM2 Gene Mutation; Liposarcoma; Urothelial Carcinoma; MPNST; Cutaneous Melanoma; Mucosal Melanoma; Malignant Peripheral Nerve Sheath Tumors; STK11 Gene Mutation
Intervention: Drug: APG-115+Pembrolizumab
Sponsors: Ascentage Pharma Group Inc.; Merck Sharp & Dohme Corp.
Recruiting -
Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)
Posted: May 16th, 2018, 2:00pm GMT
Conditions: Advanced Malignant Solid Neoplasm; Recurrent Childhood Ependymoma; Recurrent Ewing Sarcoma; Recurrent Glioma; Recurrent Hepatoblastoma; Recurrent Kidney Wilms Tumor; Recurrent Langerhans Cell Histiocytosis; Recurrent Malignant Germ Cell Tumor; Recurrent Malignant Glioma; Recurrent Medulloblastoma; Recurrent Neuroblastoma; Recurrent Non-Hodgkin Lymphoma; Recurrent Osteosarcoma; Recurrent Peripheral Primitive Neuroectodermal Tumor; Recurrent Rhabdoid Tumor; Recurrent Rhabdomyosarcoma; Recurrent Soft Tissue Sarcoma; Refractory Ependymoma; Refractory Ewing Sarcoma; Refractory Glioma; Refractory Hepatoblastoma; Refractory Langerhans Cell Histiocytosis; Refractory Malignant Germ Cell Tumor; Refractory Malignant Glioma; Refractory Medulloblastoma; Refractory Neuroblastoma; Refractory Non-Hodgkin Lymphoma; Refractory Osteosarcoma; Refractory Peripheral Primitive Neuroectodermal Tumor; Refractory Rhabdoid Tumor; Refractory Rhabdomyosarcoma; Refractory Soft Tissue Sarcoma
Interventions: Other: Laboratory Biomarker Analysis; Drug: Palbociclib; Other: Pharmacological Study
Sponsor: National Cancer Institute (NCI)
Recruiting -
Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients
Posted: March 8th, 2018, 3:00pm GMT
Condition: Mixed Tumor, Malignant
Intervention: Drug: BAY806946
Sponsor: Bayer
Recruiting -
Pediatric PET/MR Image Registry
Posted: March 8th, 2018, 3:00pm GMT
Conditions: Soft Tissue; Lymphoma; Osteosarcoma
Interventions: Diagnostic Test: PET/MR imaging; Diagnostic Test: MR imaging; Diagnostic Test: PET/CT imaging
Sponsor: Stanford University
Recruiting -
A Study of Atezolizumab (Anti-Pd-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Posted: March 2nd, 2018, 3:00pm GMT
Condition: Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Interventions: Drug: Atezolizumab; Drug: Placebo
Sponsor: Hoffmann-La Roche
Recruiting -
Phase 2 CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma
Posted: February 7th, 2018, 3:00pm GMT
Conditions: Solid Tumor; Non Small Cell Lung Cancer; Melanoma; Sarcoma; Sarcoma, Ewing; Osteosarcoma; Leiomyosarcoma; Synovial Sarcoma; Liposarcoma; Soft Tissue Sarcoma; Bone Sarcoma; Refractory Sarcoma
Interventions: Biological: CAB-AXL-ADC; Biological: PD-1 inhibitor
Sponsor: BioAtla, Inc.
Recruiting -
Project HERO: Health Empowerment & Recovery Outcomes
Posted: November 17th, 2017, 3:00pm GMT
Conditions: Prostate Cancer; Bladder Cancer; Kidney Cancer; Colon Cancer; Rectum Cancer; Thyroid Cancer; Lung Cancer; Small Intestine Cancer; Soft Tissue Cancer
Interventions: Behavioral: Body Mind Training (BMT); Behavioral: Body Training (BT):; Behavioral: Usual Care (UC)
Sponsors: Rutgers, The State University of New Jersey; University of California, Los Angeles; University of New Mexico
Recruiting -
Molecular Characterization of Viral-associated Tumors, Tumors Occurring in the Setting of HIV or Other Immune Disorders and Castleman Disease
Posted: October 4th, 2017, 2:00pm GMT
Conditions: Human Immunodeficiency Virus; Castleman's Disease; Kaposi's Sarcoma; Viral-Associated Cancer
Intervention:
Sponsor: National Cancer Institute (NCI)
Recruiting -
The Impact of Cancer on the Physical and Psychosocial Well-being Among Childhood Osteosarcoma Survivors
Posted: October 2nd, 2017, 2:00pm GMT
Condition: Childhood Osteosarcoma
Intervention: Other: Questionnaires
Sponsor: The University of Hong Kong
Recruiting -
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
Posted: July 28th, 2017, 2:00pm GMT
Conditions: Advanced Malignant Solid Neoplasm; Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma; Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma; Low Grade Glioma; Malignant Glioma; Recurrent Childhood Central Nervous System Neoplasm; Recurrent Childhood Ependymoma; Recurrent Childhood Malignant Germ Cell Tumor; Recurrent Childhood Non-Hodgkin Lymphoma; Recurrent Childhood Rhabdomyosarcoma; Recurrent Childhood Soft Tissue Sarcoma; Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Recurrent Glioma; Recurrent Hepatoblastoma; Recurrent Langerhans Cell Histiocytosis; Recurrent Malignant Solid Neoplasm; Recurrent Medulloblastoma; Recurrent Neuroblastoma; Recurrent Osteosarcoma; Refractory Childhood Malignant Germ Cell Tumor; Refractory Ependymoma; Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Refractory Glioma; Refractory Hepatoblastoma; Refractory Langerhans Cell Histiocytosis; Refractory Malignant Glioma; Refractory Malignant Solid Neoplasm; Refractory Medulloblastoma; Refractory Neuroblastoma; Refractory Non-Hodgkin Lymphoma; Refractory Osteosarcoma; Refractory Primary Central Nervous System Neoplasm; Refractory Rhabdomyosarcoma; Refractory Soft Tissue Sarcoma; Rhabdoid Tumor; Wilms Tumor
Intervention: Drug: Olaparib
Sponsor: National Cancer Institute (NCI)
Recruiting -
Biology of Osteosarcoma (BOOST) Registry and Biobank
Posted: July 21st, 2017, 2:00pm GMT
Condition: Osteosarcoma
Intervention:
Sponsor: University of Minnesota
Recruiting -
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Posted: July 18th, 2017, 2:00pm GMT
Conditions: Advanced Malignant Solid Neoplasm; Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma; Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma; Ependymoma; Ewing Sarcoma; Hepatoblastoma; Langerhans Cell Histiocytosis; Malignant Germ Cell Tumor; Malignant Glioma; Osteosarcoma; Peripheral Primitive Neuroectodermal Tumor; Recurrent Childhood Central Nervous System Neoplasm; Recurrent Childhood Non-Hodgkin Lymphoma; Recurrent Malignant Solid Neoplasm; Recurrent Neuroblastoma; Refractory Malignant Solid Neoplasm; Refractory Neuroblastoma; Refractory Non-Hodgkin Lymphoma; Refractory Primary Central Nervous System Neoplasm; Rhabdoid Tumor; Rhabdomyosarcoma; Soft Tissue Sarcoma; Wilms Tumor
Interventions: Other: Laboratory Biomarker Analysis; Drug: Vemurafenib
Sponsor: National Cancer Institute (NCI)
Recruiting -
Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Posted: July 11th, 2017, 2:00pm GMT
Conditions: Advanced Malignant Solid Neoplasm; Ann Arbor Stage III Non-Hodgkin Lymphoma; Ann Arbor Stage IV Non-Hodgkin Lymphoma; Malignant Glioma; Recurrent Ependymoma; Recurrent Ewing Sarcoma; Recurrent Glioma; Recurrent Hepatoblastoma; Recurrent Langerhans Cell Histiocytosis; Recurrent Malignant Germ Cell Tumor; Recurrent Malignant Solid Neoplasm; Recurrent Medulloblastoma; Recurrent Neuroblastoma; Recurrent Non-Hodgkin Lymphoma; Recurrent Osteosarcoma; Recurrent Peripheral Primitive Neuroectodermal Tumor; Recurrent Primary Central Nervous System Neoplasm; Recurrent Rhabdomyosarcoma; Recurrent Soft Tissue Sarcoma; Refractory Langerhans Cell Histiocytosis; Refractory Malignant Germ Cell Tumor; Refractory Malignant Solid Neoplasm; Refractory Neuroblastoma; Refractory Non-Hodgkin Lymphoma; Refractory Primary Central Nervous System Neoplasm; Rhabdoid Tumor; Stage III Osteosarcoma AJCC v7; Stage III Soft Tissue Sarcoma AJCC v7; Stage IV Osteosarcoma AJCC v7; Stage IV Soft Tissue Sarcoma AJCC v7; Stage IVA Osteosarcoma AJCC v7; Stage IVB Osteosarcoma AJCC v7; Wilms Tumor
Interventions: Other: Laboratory Biomarker Analysis; Other: Pharmacological Study; Drug: Samotolisib
Sponsor: National Cancer Institute (NCI)
Recruiting -
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
Posted: July 11th, 2017, 2:00pm GMT
Conditions: Hematopoietic and Lymphoid Cell Neoplasm; Malignant Solid Neoplasm; Recurrent Ependymoma; Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Recurrent Hepatoblastoma; Recurrent Langerhans Cell Histiocytosis; Recurrent Malignant Germ Cell Tumor; Recurrent Malignant Glioma; Recurrent Medulloblastoma; Recurrent Neuroblastoma; Recurrent Non-Hodgkin Lymphoma; Recurrent Osteosarcoma; Recurrent Rhabdomyosarcoma; Recurrent Soft Tissue Sarcoma; Recurrent WHO Grade II Glioma; Refractory Ependymoma; Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Refractory Hepatoblastoma; Refractory Langerhans Cell Histiocytosis; Refractory Malignant Germ Cell Tumor; Refractory Malignant Glioma; Refractory Medulloblastoma; Refractory Neuroblastoma; Refractory Non-Hodgkin Lymphoma; Refractory Osteosarcoma; Refractory Rhabdomyosarcoma; Refractory Soft Tissue Sarcoma; Wilms Tumor
Interventions: Drug: Ensartinib; Other: Laboratory Biomarker Analysis; Other: Pharmacological Study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group
Recruiting -
Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)
Posted: July 11th, 2017, 2:00pm GMT
Conditions: Advanced Malignant Solid Neoplasm; Recurrent Ependymoma; Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Recurrent Glioma; Recurrent Hepatoblastoma; Recurrent Langerhans Cell Histiocytosis; Recurrent Malignant Germ Cell Tumor; Recurrent Malignant Glioma; Recurrent Malignant Solid Neoplasm; Recurrent Medulloblastoma; Recurrent Neuroblastoma; Recurrent Non-Hodgkin Lymphoma; Recurrent Osteosarcoma; Recurrent Rhabdoid Tumor; Recurrent Rhabdomyosarcoma; Recurrent Soft Tissue Sarcoma; Refractory Ependymoma; Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Refractory Glioma; Refractory Hepatoblastoma; Refractory Langerhans Cell Histiocytosis; Refractory Malignant Germ Cell Tumor; Refractory Malignant Glioma; Refractory Malignant Solid Neoplasm; Refractory Neuroblastoma; Refractory Non-Hodgkin Lymphoma; Refractory Osteosarcoma; Refractory Primary Central Nervous System Neoplasm; Refractory Rhabdoid Tumor; Refractory Rhabdomyosarcoma; Wilms Tumor
Interventions: Drug: Larotrectinib; Drug: Larotrectinib Sulfate
Sponsor: National Cancer Institute (NCI)
Recruiting -
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
Posted: July 7th, 2017, 2:00pm GMT
Conditions: Advanced Malignant Solid Neoplasm; Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma; Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma; Low Grade Glioma; Malignant Glioma; Recurrent Childhood Ependymoma; Recurrent Childhood Malignant Germ Cell Tumor; Recurrent Childhood Medulloblastoma; Recurrent Childhood Non-Hodgkin Lymphoma; Recurrent Childhood Rhabdomyosarcoma; Recurrent Childhood Soft Tissue Sarcoma; Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Recurrent Hepatoblastoma; Recurrent Langerhans Cell Histiocytosis; Recurrent Malignant Solid Neoplasm; Recurrent Neuroblastoma; Recurrent Osteosarcoma; Recurrent Primary Central Nervous System Neoplasm; Refractory Langerhans Cell Histiocytosis; Refractory Malignant Solid Neoplasm; Refractory Neuroblastoma; Refractory Non-Hodgkin Lymphoma; Refractory Primary Central Nervous System Neoplasm; Rhabdoid Tumor; Stage III Soft Tissue Sarcoma AJCC v7; Stage IV Soft Tissue Sarcoma AJCC v7; Wilms Tumor
Interventions: Drug: Erdafitinib; Other: Laboratory Biomarker Analysis; Other: Pharmacological Study
Sponsor: National Cancer Institute (NCI)
Recruiting -
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
Posted: May 16th, 2017, 2:00pm GMT
Conditions: Advanced Malignant Solid Neoplasm; Ann Arbor Stage III Non-Hodgkin Lymphoma; Ann Arbor Stage IV Non-Hodgkin Lymphoma; Histiocytic Sarcoma; Juvenile Xanthogranuloma; Langerhans Cell Histiocytosis; Malignant Glioma; Recurrent Childhood Rhabdomyosarcoma; Recurrent Ependymoma; Recurrent Ewing Sarcoma; Recurrent Glioma; Recurrent Hepatoblastoma; Recurrent Langerhans Cell Histiocytosis; Recurrent Malignant Germ Cell Tumor; Recurrent Malignant Solid Neoplasm; Recurrent Medulloblastoma; Recurrent Neuroblastoma; Recurrent Non-Hodgkin Lymphoma; Recurrent Osteosarcoma; Recurrent Peripheral Primitive Neuroectodermal Tumor; Recurrent Primary Central Nervous System Neoplasm; Recurrent Rhabdoid Tumor; Recurrent Soft Tissue Sarcoma; Refractory Ewing Sarcoma; Refractory Glioma; Refractory Hepatoblastoma; Refractory Langerhans Cell Histiocytosis; Refractory Malignant Germ Cell Tumor; Refractory Malignant Solid Neoplasm; Refractory Medulloblastoma; Refractory Neuroblastoma; Refractory Non-Hodgkin Lymphoma; Refractory Osteosarcoma; Refractory Peripheral Primitive Neuroectodermal Tumor; Refractory Primary Central Nervous System Neoplasm; Refractory Rhabdoid Tumor; Refractory Rhabdomyosarcoma; Rhabdoid Tumor; Stage III Osteosarcoma AJCC v7; Stage III Soft Tissue Sarcoma AJCC v7; Stage IV Osteosarcoma AJCC v7; Stage IV Soft Tissue Sarcoma AJCC v7; Stage IVA Osteosarcoma AJCC v7; Stage IVB Osteosarcoma AJCC v7; Wilms Tumor
Interventions: Procedure: Biopsy; Procedure: Biospecimen Collection; Drug: Ensartinib; Drug: Erdafitinib; Other: Laboratory Biomarker Analysis; Drug: Larotrectinib; Procedure: Mutation Carrier Screening; Drug: Olaparib; Drug: Palbociclib; Other: Pharmacological Study; Drug: Samotolisib; Drug: Selpercatinib; Drug: Selumetinib Sulfate; Drug: Tazemetostat; Drug: Tipifarnib; Drug: Ulixertinib; Drug: Vemurafenib
Sponsor: National Cancer Institute (NCI)
Recruiting -
Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma
Posted: October 26th, 2016, 2:00pm GMT
Conditions: Osteosarcoma; Ewing Sarcoma; Rhabdomyosarcoma; Soft Tissue Sarcoma
Interventions: Drug: nab-Paclitaxel; Drug: Gemcitabine
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; National Pediatric Cancer Foundation
Recruiting -
Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases
Posted: August 9th, 2016, 2:00pm GMT
Conditions: Esophageal Neoplasms; Lung Neoplasms; Mesothelioma; Thymus Neoplasms; Neoplasms, Germ Cell and Embryonal
Intervention: Drug: Mithramycin
Sponsor: National Cancer Institute (NCI)
Recruiting -
Randomized Carbon Ions vs Standard Radiotherapy for Radioresistant Tumors
Posted: July 20th, 2016, 2:00pm GMT
Condition: Malignant Tumors as Chordoma, Adenoid Cystic Carcinoma and Sarcoma
Interventions: Radiation: Carbon ions therapy; Radiation: Advanced external radiotherapy by Xrays or protons
Sponsor: Hospices Civils de Lyon
Recruiting -
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Posted: July 15th, 2016, 2:00pm GMT
Conditions: Acinar Cell Carcinoma; Adenoid Cystic Carcinoma; Adrenal Cortex Carcinoma; Adrenal Gland Pheochromocytoma; Anal Canal Neuroendocrine Carcinoma; Anal Canal Undifferentiated Carcinoma; Angiosarcoma; Apocrine Neoplasm; Appendix Mucinous Adenocarcinoma; Bartholin Gland Transitional Cell Carcinoma; Basal Cell Carcinoma; Bladder Adenocarcinoma; Breast Metaplastic Carcinoma; Cervical Adenocarcinoma; Cholangiocarcinoma; Chordoma; Colorectal Squamous Cell Carcinoma; Desmoid Fibromatosis; Endometrial Transitional Cell Carcinoma; Endometrioid Adenocarcinoma; Esophageal Neuroendocrine Carcinoma; Esophageal Undifferentiated Carcinoma; Extrahepatic Bile Duct Carcinoma; Extramammary Paget Disease; Fallopian Tube Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Fibromyxoid Tumor; Gallbladder Carcinoma; Gastric Neuroendocrine Carcinoma; Gastric Squamous Cell Carcinoma; Gastric Undifferentiated Carcinoma; Gastrointestinal Stromal Tumor; Gestational Trophoblastic Tumor; Giant Cell Carcinoma; Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type; Intestinal Neuroendocrine Carcinoma; Intrahepatic Cholangiocarcinoma; Lung Carcinoid Tumor; Lung Sarcomatoid Carcinoma; Major Salivary Gland Carcinoma; Malignant Odontogenic Neoplasm; Malignant Peripheral Nerve Sheath Tumor; Malignant Solid Neoplasm; Malignant Testicular Sex Cord-Stromal Tumor; Metastatic Malignant Neoplasm of Unknown Primary; Minimally Invasive Lung Adenocarcinoma; Mixed Mesodermal (Mullerian) Tumor; Mucinous Adenocarcinoma; Mucinous Cystadenocarcinoma; Nasal Cavity Adenocarcinoma; Nasal Cavity Carcinoma; Nasopharyngeal Carcinoma; Nasopharyngeal Papillary Adenocarcinoma; Nasopharyngeal Undifferentiated Carcinoma; Oral Cavity Carcinoma; Oropharyngeal Undifferentiated Carcinoma; Ovarian Adenocarcinoma; Ovarian Germ Cell Tumor; Ovarian Mucinous Adenocarcinoma; Ovarian Squamous Cell Carcinoma; Ovarian Transitional Cell Carcinoma; Pancreatic Acinar Cell Carcinoma; Pancreatic Neuroendocrine Carcinoma; Paraganglioma; Paranasal Sinus Adenocarcinoma; Paranasal Sinus Carcinoma; Parathyroid Gland Carcinoma; PEComa; Peritoneal Mesothelioma; Pituitary Gland Carcinoma; Placental Choriocarcinoma; Primary Peritoneal High Grade Serous Adenocarcinoma; Pseudomyxoma Peritonei; Rare Disorder; Scrotal Squamous Cell Carcinoma; Seminal Vesicle Adenocarcinoma; Seminoma; Serous Cystadenocarcinoma; Small Intestinal Adenocarcinoma; Small Intestinal Squamous Cell Carcinoma; Spindle Cell Neoplasm; Squamous Cell Carcinoma of the Penis; Teratoma With Somatic-Type Malignancy; Testicular Non-Seminomatous Germ Cell Tumor; Thyroid Gland Carcinoma; Tracheal Carcinoma; Transitional Cell Carcinoma; Ureter Adenocarcinoma; Ureter Squamous Cell Carcinoma; Urethral Adenocarcinoma; Urethral Squamous Cell Carcinoma; Vaginal Adenocarcinoma; Vaginal Squamous Cell Carcinoma, Not Otherwise Specified; Vulvar Carcinoma
Interventions: Procedure: Biospecimen Collection; Biological: Ipilimumab; Biological: Nivolumab
Sponsor: National Cancer Institute (NCI)
Recruiting -
PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors
Posted: October 22nd, 2015, 2:00pm GMT
Conditions: Sarcoma; Malignant Peripheral Nerve Sheath Tumors
Interventions: Drug: PLX3397; Drug: Sirolimus
Sponsors: Gulam Manji; Daiichi Sankyo, Inc.
Recruiting -
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Posted: October 5th, 2015, 2:00pm GMT
Conditions: Breast Cancer; Cholangiocarcinoma; Colorectal Cancer; Head and Neck Neoplasms; Lymphoma, Large-Cell, Anaplastic; Melanoma; Neuroendocrine Tumors; Non-Small Cell Lung Cancer; Ovarian Cancer; Pancreatic Cancer; Papillary Thyroid Cancer; Primary Brain Tumors; Renal Cell Carcinoma; Sarcomas; Salivary Gland Cancers; Adult Solid Tumor
Intervention: Drug: Entrectinib
Sponsor: Hoffmann-La Roche
Recruiting -
Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma
Posted: October 5th, 2015, 2:00pm GMT
Conditions: Alveolar Rhabdomyosarcoma; Botryoid-Type Embryonal Rhabdomyosarcoma; Embryonal Rhabdomyosarcoma; Rhabdomyosarcoma; Sclerosing Rhabdomyosarcoma; Spindle Cell Rhabdomyosarcoma
Interventions: Drug: Cyclophosphamide; Biological: Dactinomycin; Drug: Irinotecan Hydrochloride; Other: Laboratory Biomarker Analysis; Other: Questionnaire Administration; Radiation: Radiation Therapy; Drug: Temsirolimus; Drug: Vincristine Sulfate; Drug: Vinorelbine
Sponsor: National Cancer Institute (NCI)
Recruiting -
Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers
Posted: December 25th, 2013, 3:00pm GMT
Conditions: Cervical Adenocarcinoma; Cervical Adenosarcoma; Cervical Adenosquamous Carcinoma; Cervical Carcinosarcoma; Cervical Squamous Cell Carcinoma, Not Otherwise Specified; Endometrial Adenosquamous Carcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Endometrioid Adenocarcinoma; Endometrial Mixed Cell Adenocarcinoma; Endometrial Mucinous Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Undifferentiated Carcinoma; Fallopian Tube Adenocarcinoma; Fallopian Tube Carcinosarcoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Squamous Cell Carcinoma; Fallopian Tube Transitional Cell Carcinoma; Fallopian Tube Undifferentiated Carcinoma; High Grade Ovarian Serous Adenocarcinoma; Malignant Female Reproductive System Neoplasm; Malignant Ovarian Clear Cell Tumor; Malignant Ovarian Endometrioid Tumor; Malignant Ovarian Epithelial Tumor; Malignant Ovarian Mucinous Tumor; Malignant Peritoneal Neoplasm; Malignant Solid Neoplasm; Ovarian Carcinosarcoma; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Serous Adenocarcinoma; Ovarian Transitional Cell Carcinoma; Ovarian Undifferentiated Carcinoma; Platinum-Resistant Fallopian Tube Carcinoma; Platinum-Resistant Ovarian Carcinoma; Platinum-Resistant Primary Peritoneal Carcinoma; Platinum-Sensitive Ovarian Carcinoma; Primary Peritoneal Carcinosarcoma; Primary Peritoneal Clear Cell Adenocarcinoma; Primary Peritoneal Serous Adenocarcinoma; Primary Peritoneal Transitional Cell Carcinoma; Primary Peritoneal Undifferentiated Carcinoma; Stage IV Cutaneous Melanoma AJCC v6 and v7; Unresectable Melanoma; Uterine Corpus Carcinosarcoma
Interventions: Biological: Bevacizumab; Other: Laboratory Biomarker Analysis; Drug: Nab-paclitaxel; Other: Pharmacological Study
Sponsors: Mayo Clinic; National Cancer Institute (NCI)
Recruiting -
Comprehensive Omics Analysis of Pediatric Solid Tumors and Establishment of a Repository for Related Biological Studies
Posted: April 23rd, 2010, 2:00pm GMT
Conditions: Sarcoma; Endocrine Tumors; Neuroblastoma; Retinoblastoma; Renal Cancer
Intervention:
Sponsor: National Cancer Institute (NCI)
Recruiting -
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies
Posted: August 18th, 2008, 2:00pm GMT
Conditions: Acute Lymphoblastic Leukemia; Brain Neoplasm; Hematopoietic Cell Transplantation Recipient; Hodgkin Lymphoma; Osteosarcoma; Rhabdomyosarcoma
Interventions: Procedure: Assessment of Therapy Complications; Other: Questionnaire Administration
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting